Christopher M Lindblom Net Worth

The estimated Net Worth of Christopher M Lindblom is at least $278 dollars as of 26 November 2012. Christopher Lindblom owns over 13,885 units of Infinity Pharmaceuticals stock worth over $278 and over the last 17 years Christopher sold INFI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Christopher Lindblom INFI stock SEC Form 4 insiders trading

Christopher has made over 1 trades of the Infinity Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently Christopher exercised 13,885 units of INFI stock worth $181,338 on 26 November 2012.

The largest trade Christopher's ever made was exercising 13,885 units of Infinity Pharmaceuticals stock on 26 November 2012 worth over $181,338. On average, Christopher trades about 1,389 units every 0 days since 2007. As of 26 November 2012 Christopher still owns at least 13,885 units of Infinity Pharmaceuticals stock.

You can see the complete history of Christopher Lindblom stock trades at the bottom of the page.

What's Christopher Lindblom's mailing address?

Christopher's mailing address filed with the SEC is C/O INFINITY PHARMACEUTICALS INC, 780 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.

Insiders trading at Infinity Pharmaceuticals

Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over $485,846,497 worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth $175,155,554 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $14,976. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth $15,363.

What does Infinity Pharmaceuticals do?

the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business

Complete history of Christopher Lindblom stock trades at Infinity Pharmaceuticals

Infinity Pharmaceuticals executives and stock owners

Infinity Pharmaceuticals executives and other stock owners filed with the SEC include:

• Adelene Perkins,
  Chairman of the Board, Chief Executive Officer
• Samuel Agresta,
  Director
• Lawrence Bloch,
  President, Treasurer
• Adelene Q. Perkins,
  Chairman & CEO
• Seth Tasker,
  Senior Vice President, Chief Business Officer and Secretary
• Dr. Lawrence E. Bloch,
  Pres & Treasurer
• Dr. Robert Ilaria Jr., M.D.,
  Chief Medical Officer
• Dr. Stephane Peluso Ph.D.,
  Chief Scientific Officer
• Seth A. Tasker,
  Sr. VP, Chief Bus. Officer & Sec.
• Michael Venuti,
  Independent Director
• Richard Gaynor,
  Independent Director
• Anthony Evnin,
  Independent Director
• David Beier,
  Independent Director
• Norman Selby,
  Lead Independent Director
• Seth A. Tasker J.D.,
  Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec.
• Dr. Jeffery L. Kutok M.D., Ph.D.,
  Chairman of Scientific Advisory Board
• Dr. Lawrence E. Bloch J.D., M.D.,
  Pres & Treasurer
• Jayne Kauffman,
  Sr. Exec. Coordinator
• Rossitza Alargova Ph.D.,
  Head of Pharmaceutical Devel.
• Dr. Jeffery L. Kutok,
  Chairman of Scientific Advisory Board
• Melissa Hackel,
  VP of Fin.
• Michael Kauffman,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Jeffery Kutok,
  Chief Scientific Officer
• Ian F Smith,
  Director
• Christopher M Lindblom,
  Assistant Treasurer
• Jeffrey Berkowitz,
  Director
• Jose Baselga,
  Director
• Eric S Lander,
  Director
• Thomas J. Jr. Lynch,
  Director
• Patrick Pak Tin Lee,
  Director
• Medical Co L.P. Rosebay,
  10% owner
• Steven H Holtzman,
  CEO and Assistant Secretary
• Martin Babler,
  Director
• David Roth,
  Chief Medical Officer
• Winselow S. Jr. Tucker,
  Vice President, Marketing
• Gwen A. Fyfe,
  Director
• Joshua Hamermesh,
  See Remarks
• Co Beacon,
  10% owner
• Winston K.C. Lam,
  General Counsel
• Gerald E Quirk,
  VP,Cor. Affairs & Gnrl Counsel
• Vito J. Palombella,
  Chief Scientific Officer
• Thomas Joseph Burke,
  Assistant Treasurer
• Harry F Jr Hixson,
  Director
• Vicki L Sato,
  Director
• Jeffrey K Tong,
  VP, Cor. & Product Development
• Herm Rosenman,
  Director
• Arnold J Levine,
  Director
• James B Tananbaum,
  Director
• D Ronald Daniel,
  Director
• Franklin Moss,
  Director
• William C Jr Bertrand,
  General Counsel
• Sujay Kango,
  
• Partners L P/Ilbiotechnolog...,
  
• Stephane Peluso,
  Chief Scientific Officer
• Robert Jr. Ilaria,
  Chief Medical Officer
• Brian Schwartz,